Back to Journals » Cancer Management and Research » Volume 9

The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor

Authors Chen Y, Guo W, Fan J, Chen Y, Zhang X, Chen X, Luo P

Received 8 September 2017

Accepted for publication 26 October 2017

Published 7 December 2017 Volume 2017:9 Pages 801—811

DOI https://doi.org/10.2147/CMAR.S151235

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo

Video abstract presented by Jiaqi Ye on behalf of Chen et al

Views: 29

Yating Chen,1,* Wenjie Guo,1,* Junsheng Fan,2,* Yuqing Chen,1 Xiaoli Zhang,1 Xin Chen,1 Peng Luo1

1Department of Respiratory, Zhujiang Hospital of Southern Medical University, Guangzhou, China; 2Department of Respiratory, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China

*These authors contributed equally to this work

Abstract: With the clinical promotion of precision medicine and individualized medical care, molecular targeted medicine has been used to treat non-small cell lung cancer (NSCLC) patients and proved to be significantly effective. Anaplastic lymphoma kinase (ALK) inhibitor is one of the most important specific therapeutic agents for patients with ALK-positive NSCLC. It can extend the survival of patients. However, resistance to the ALK inhibitor inevitably develops in the application process. So, the real-time resistance surveillance is particularly important, and liquid biopsy is one of the most potential inspection methods. Circulating tumor cells, circulating free tumor DNA and exosome in body fluid are used as the main detection biomarkers to reflect the occurrence of resistance in real time through sequencing or counting and then to guide the follow-up treatment.

Keywords: NSCLC, ALK, resistance, liquid biopsy, CTCs, ctDNA, exosome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer

Guo WJ, Liu SH, Zhang XL, Chen YT, Qian RL, Zou ZY, Chen X, Luo P

Drug Design, Development and Therapy 2017, 11:3367-3376

Published Date: 28 November 2017